5 Key Takeaways

• 1

  Survodutide significantly reduced body weight in patients with obesity over 76 weeks compared to placebo in the phase 3 SYNCHRONIZE-1 trial.

• 2

  Patients receiving survodutide 3.6 mg and 6.0 mg achieved mean weight losses of approximately 12% and 13%, respectively, versus over 5% for placebo.

• 3

  Higher percentages of patients on survodutide achieved substantial weight loss thresholds: 55% and 57% lost at least 10%, compared to 26% on placebo.

• 4

  Survodutide also led to greater reductions in waist circumference and improvements in metabolic markers compared to placebo.

• 5

  Adverse gastrointestinal events were more common in survodutide groups, with discontinuation rates due to these events at 18% and 20%.